PHARMASGP HOLDING SE O.N.
PHARMASGP HOLDING SE O.N./ DE000A2P4LJ5 /
PSG
6/7/2023 5:36:23 PM
|
Chg.
+0.300
|
Volume |
Bid6/7/2023 |
Ask6/7/2023 |
Market Capitalization |
Dividend Y. |
P/E Ratio |
27.700EUR
|
+1.09%
|
379 Turnover: 10,516.700 |
-Bid Size: - |
-Ask Size: - |
324 mill.EUR |
1.67% |
30.34 |
Business description
PharmaSGP is a pure-play consumer health company with a broad portfolio of leading chemical-free non-prescription pharmaceuticals sold over the counter (“OTC”) and other healthcare products. PharmaSGP’s products are sold exclusively through pharmacies. Its products are based on natural active pharmaceutical ingredients with documented efficacy and fewer known side effects than most chemical-based pharmaceuticals. The Company’s core brands cover chronic indications, including pain and other age-related ailments. In Germany, PharmaSGP is the market leader for systemic chemical-free pain remedies with its brand families RUBAXX® for rheumatic pain and RESTAXIL® for neuralgic pain. Furthermore, PharmaSGP has introduced leading products against sexual weakness and vertigo symptoms.
Management board & Supervisory board
CEO |
Natalie Weigand |
Management board |
Michael Rudolf |
Supervisory board |
Dr. Clemens Fischer, Madlena Hohlefelder, Dr. Axel Rebien |
Company data
Name: |
PharmaSGP Holding SE |
Address: |
Lochhamer Schlag 21,D-82166 Gräfelfing |
Phone: |
+49-611-2058-5528 |
Fax: |
+49-611-2058-5566 |
E-mail: |
info@pharmasgp.com
|
Internet: |
https://pharmasgp.com/ |
Industry: |
Healthcare |
Sector: |
Pharmaceutical Industry |
Sub sector: |
Pharmaceuticals |
End of financial year: |
12/31 |
Free Float: |
- |
IPO date: |
6/19/2020 |
Investor relations
Name: |
Claudius Krause |
IR phone: |
+49-611-2058-5535 |
IR Fax: |
- |
IR e-mail: |
ir@pharmasgp.com
|
Main Shareholders
FUTRUE GmbH / MVH Beteiligungs- und Beratungs-GmbH |
|
77.82% |
Freefloat |
|
14.83% |
Union Investment Privatfonds GmbH |
|
4.70% |
Swedbank Robur Fonder AB |
|
2.65% |